Recently, Dizal Pharma announced the completion of a US$100 million Series A financing for the research and development of small molecules.
This round was led by Lilly Asia Ventures.
Sequoia Capital, Trinity Innovation Fund and other internationally renowned biomedical funds participated in the investment and received strategic support from Wuxi's government fund.
Dizal Pharma decided to establish a China headquarters in Wuxi High-tech Zone, and invest in the establishment of R&D, operation, production, sales and distribution centers in stages.
It will actively create a cutting-edge, practical and characteristic innovative drug ecosystem, attracting partners from the R&D, capital, and industrial circles, and jointly promote the development of innovative drugs in Wuxi and even China.